Document:

EX-10.1

 Exhibit 10.1 

[TRANSLATION COPY] 

Settlement 
 § 1

 Termination of Contract 
  

	1.	The Defendant II (i.e. Teradata GmbH) and the Claimant agree that their employment relationship will terminate with effect to March 31st, 2017
(“Termination Date”). 

  

	2.	The Defendant I (i.e. Teradata Corporation) and the Claimant agree that any employment relationship between the Defendant I and the Claimant will also terminate with effect to the Termination Date.

  

	3.	The Parties agree that, with effect to the Termination Date, any further potential service or employment relationships between the Claimant and any affiliated company of the Defendant I will also terminate. The Claimant
shall not derive any claims from such service or employment relationships. 

  

	4.	The Claimant remains irrevocably released from his duty to perform services with continued payment of his remuneration according to Sec. 2 para. (1) of this Settlement Agreement until the Termination Date.
Potential outstanding holiday entitlements and potential overtime will be set off against the period of release. 

 § 2

 Settlement of Contract 
  

	1.	Until the Termination Date, the monthly fix salary, based on an annual salary in the amount of 486,510.00 EUR gross, will be accounted for and paid to the Claimant in accordance with the terms of his Employment
Contract, i.e. a monthly amount of 40,542.50 EUR gross until the Termination Date. 

  

	2.	For the fiscal year 2016, the Defendant II pays to the Claimant the annual incentive earned under the 2016 Annual Incentive Plan of the Defendant I, at the actual performance of the Defendant I in the fiscal year 2016
of 102%, i.e. an amount of 545,864.00 EUR gross. The payment will be made in a lump sum at the point in time regulated in the 2016 Annual Incentive Plan, no later than in March 2017. 

 

	3.	For the fiscal year 2017, the Defendant II pays to the Claimant – pro rata temporis for the period of time between January 1st, 2017 to March 31st, 2017 – 3/12 of the annual incentive earned under the 2017 Annual Incentive Plan of the Defendant I, under the fiction of an actual performance of the Defendant I in the fiscal year 2017 of
100%, i.e. an amount of 133,790.25 EUR gross. The payment will be made on the Termination Date. 

  

	4.	The Claimant’s participation in the pension scheme according to the Pension Plan of the Defendant II will remain unchanged until the Termination Date. 

 

	5.	Any further claims to remuneration or bonus payments of the Claimant do not exist. 

  

	6.	The Defendant II will continue to pay for the Claimant’s expenses for housing and utilities (natural gas, water, electric, phone, cable) based on the currently applicable expatriate assignment agreement until July
15th, 2017. In case of a repatriation until end of May 2018, the Claimant will be reimbursed for the following costs according to the Assignment Agreement: 

 

	 	•	 	Relocation allowance equal to 10,000.00 USD (net of taxes) 

  

	 	•	 	Costs of business class airfare for the Employee and accompanying dependent family members 

  

	 	•	 	Costs for moving and shipment of household goods and personal effects (similar quantity and capacity as way to the USA) 

  

	7.	The Claimant is entitled to use for private purposes in accordance with the existing arrangements the company car (2015 BMW X5, AWD 4dr xDrive 35l) provided to him until the Termination Date. In accordance with the
Teradata “Vehicle Lease/Allowance Policy” the Employee is entitled to use the company car for private purposes. The private use of the company car will be subject to taxation according to tax laws applicable from time to time and the
Claimant shall be responsible for such taxes to be paid on the private use of the car. 

	8.	The Defendant II will reimburse the Claimant for his attorney’s fees occurred in relation to the termination of his employment relationship with the Defendant II upon proper evidence (proper invoice) in the amount
of 56,308.95 EUR plus VAT as a lump sum. 

  

	9.	Until the Termination Date, the Claimant remains to the full extent bound by the non-competition obligation according to Sec. 7 of the Employment Contract. 

 

	10.	The Claimant is entitled to assume the office as General Manager International with ForgeRock GmbH, Duesseldorf, Germany and to provide services for such corporation with effect from March 2nd, 2017. 

 § 3 

Severance Payment 
  

	1.	The Defendant II shall pay to the Claimant a severance payment in the amount of 3,060,000.00 USD gross. 

  

	2.	The severance payment becomes due and payable as of the Termination Date and will be paid in “Euro” in Germany. With respect to the exchange of the amount in USD agreed upon in para. 1 into Euro, the Euro
reference quotation issued by the European Central Bank (ECB) on March 30th, 2017 applies. 

  

	3.	Except as provided in the immediately following sentence, the Parties agree that this Settlement Agreement supersedes and replaces the severance terms under any plan, program, policy or practice or contract or agreement
of the Defendant II and its affiliated companies, and that the Defendant II and its affiliated companies have no further obligations to the Claimant under any plan, program, policy or practice or contract or agreement, including without limitation,
the Change in Control Severance Plan of the Defendant I (“CIC Plan”). The Claimant is no longer a Participant in the CIC Plan; provided, however, that if a change in control (as defined in the CIC Plan) occurs on or prior to the
Termination Date, then the Claimant shall be entitled to receive the greater of (1) the benefits to which he would have been entitled under the CIC Plan had he not been removed as a Participant in the CIC Plan, or (2) the severance payment
set forth in Sec 4, para. (1) of this Settlement Agreement, but in no event shall the Claimant be entitled to receive both such severance payment and the CIC Plan benefits. If a change in control occurs after the Termination Date, then the
Claimant shall have no right to benefits based on the CIC Plan. 

 § 4 

Equity Award 
  

	1.	The Parties agree that Attachment 1 provides a complete and accurate listing of all outstanding equity awards held by the Claimant (the “Equity Awards”), along with the applicable pro-ration factors for the Claimant’s time-based restricted share units, and the number of vested shares underlying the Claimants’s stock options. 

 

	2.	Any vested restricted share units as a result of this Settlement Agreement will be distributed to the Claimant in accordance with the terms, and subject to the conditions, of the applicable award agreements, including
the 6-month delay on payouts for service-based restricted share units. 

  

	3.	Solely for purposes of determining the Claimants’s rights with respect to the outstanding equity awards held by the Claimant as of the Termination Date under the Company’s equity compensation plans: The
Claimant’s employment shall be deemed to have terminated employment as a result of a “reduction-in-force” for purposes of determining the vesting
treatment of the Claimant’s service-based restricted share units and performance-based restricted share units. All vested stock options held by the Claimant shall remain exercisable until the earlier of three years after the Termination Date or
the expiration of the remainder of the stated ten-year term of the option. 

  

	4.	The Defendants shall have no obligation to grant additional equity compensation awards to the Claimant for the 2015-2016 long-term equity program grant cycle, the 2016-2017 long-term equity program grant cycle or any
subsequent cycle and will not grant such awards to the Claimant. 

 § 5 

The Claimant is obliged to return to the Defendants all items belonging to the Defendants which are in the Claimant’s possession. 

§ 6 
 Discharge

 With the fulfillment of the obligations according to this Settlement Agreement, all mutual claims of the Parties resulting from the employment
relationship and its termination, based on whatever legal grounds, known or unknown, are satisfied.EXHIBIT
10.1

 

LICENSE
AGREEMENT

 

THIS
LICENSE AGREEMENT (the “Agreement”) dated as of the last date provided for on the signature page hereto (the
“Effective Date”), is entered into between Richard L. Lindstrom, M.D.,
an individual (“Lindstrom”), with a principal place of business at 2811 Westwood Road, Wayzata, Minnesota 55391
and Imprimis Pharmaceuticals, Inc., a Delaware corporation (“Imprimis”), with a principal place of business
at 12264 El Camino Real, Suite 350, San Diego, California 92130. The parties hereby agree as follows:

 

1.       Definitions.
For the purposes of this Agreement, the following terms shall have the respective meanings set forth below and grammatical variations
of such terms shall have corresponding meanings:

 

1.1       “Affiliate”
shall mean, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under
common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, more than fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly
or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means
whatsoever.

 

1.2       “Combination
Product” shall mean a Product in the form of a combination product containing any such Product and other additional
active pharmaceutical ingredients and/or any additional active excipients uncovered by the existing intellectual property rights.

 

1.3       “First
Commercial Sale” shall mean, with respect to any Product, the first sale of such Product to a Third Party.

 

1.4       “Licensed
IP Rights” shall mean, collectively, the Licensed Patent Rights and the Licensed Know-How Rights.

 

1.5       “Licensed
Know-How Rights” shall mean all trade secret and other know-how rights in and to all data, information, compositions
and other technology (including, but not limited to, formulae, procedures, processes, methods, protocols, techniques and results
of experimentation and testing) which are necessary or useful for Imprimis to make, use, develop, sell or market the Product,
or to practice any method or process, at any time claimed or disclosed in any issued patent or pending patent application within
the Licensed Patent Rights or which otherwise relates to the Product or derivatives, enhancements, improvements and other modifications
thereof, or methods of manufacture or uses of any of the foregoing that are subject to patents or patent applications that share
common priority date with the patents and patent applications listed on Exhibit A.

 

    	Page 1 of 12 

    	 

    

 

1.6       “Licensed
Patent Rights” shall mean (a) the patents and patent applications listed on Exhibit A, (b) all worldwide
patents and patent applications that claim or cover the Product, or derivatives, enhancements, improvements and other modifications
thereof, or methods of manufacture or uses of any of the foregoing, that share common priority date with the patents and patent
applications listed on Exhibit A, in each case, in which Lindstrom heretofore or hereafter has an ownership or (sub)licensable
interest, (c) all divisions, continuations, continuations-in-part, that claim priority to, or common priority with, the patent
applications described in clauses (a) and (b) above or the patent applications that resulted in the patents described in clauses
(a) and (b) above, (d) all patents that have issued or in the future issue from any of the foregoing described patent applications,
including utility model, and (e) all extensions, supplemental protection certificates, registrations, confirmations, reissues,
reexaminations, inter partes reviews, post-grant reviews, restorations, additions and renewals of or to any of the foregoing described
patents.

 

1.7       “Net
Sales” shall mean, with respect to any Product, the gross sales price of such Product invoiced by the Company and its
Affiliates to customers who are not Affiliates (or are Affiliates but are the end users of such Product) less: (a) credits, allowances,
discounts and rebates to, and chargebacks from the account of, such customers; (b) freight and insurance costs in transporting
such Product; (c) cash, quantity and trade discounts, rebates and other price reductions for such Product; (d) sales, use, value-added
and other direct taxes; (e) customs duties, tariffs, surcharges and other governmental charges incurred in exporting or importing
such Product; (f) an allowance for uncollectible or bad debts determined in accordance with accounting principles generally accepted
in the United States of America (“GAAP”); and (g) any fees and expenses associated with the protection of the
intellectual property rights underlying the Product.

 

1.8       “Person”
shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization or other entity, as
well as any syndicate or group of any of the foregoing.

 

1.9       “Product”
shall mean services, compositions, products, dosages and formulations that are claimed or covered by the Licensed Patent Rights
or use the Licensed Know-How Rights.

 

1.10       “Royalty
Period” shall mean the period of time beginning on the date of the First Commercial Sale of the Product and continuing
during the term for which a Valid Claim remains in effect and would be infringed but for rights under the Licensed Patent Rights
by the make, use, offer for sale, sale or import of such Product.

 

1.11       “Third
Party” shall mean any Person other than Imprimis, Lindstrom or their respective Affiliates.

 

1.12       “Valid
Claim” shall mean either (a) a claim of an issued and unexpired patent included within the Licensed Patent Rights, which
has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise or (b) a claim of a pending patent application included within the Licensed
Patent Rights, which claim was filed in good faith, has not been pending for more than five (5) years and has not been abandoned
or finally disallowed without the possibility of appeal or refiling of such application.

 

    	Page 2 of 12 

    	 

    

 

2.       Representations
and Warranties

 

2.1       Mutual
Representations and Warranties. Each party hereby represents and warrants to the other party as follows:

 

2.1.1       Such
party, if an entity, is a corporation duly organized, validly existing and in good standing under the laws of the state in which
it is incorporated.

 

2.1.2       Such
party (a) has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement
and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such party,
and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms.

 

2.1.3       All
necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by
such party in connection with this Agreement have been obtained.

 

2.1.4       The
execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do not conflict with
or violate any requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any
contractual obligation of it.

 

2.2       Lindstrom
Representations and Warranties. Lindstrom hereby represents and warrants to Imprimis as follows:

 

2.2.1       Lindstrom
(a) is the sole owner or exclusive licensee of the Licensed IP Rights, (b) has not granted to any Third Party any license or other
interest in the Licensed IP Rights, (c) is not aware of any Third Party patent, patent application or other intellectual property
rights that would be infringed (i) by practicing any process or method or by making, using or selling any composition which is
claimed or disclosed in the Licensed Patent Rights or which constitutes Licensed Know-How Rights, or (ii) by making, using or
selling Product, and (d) is not aware of any widespread or commercial scale infringement or misappropriation by a Third Party
of the Licensed IP Rights.

 

2.3       Imprimis
Representations and Warranties. Imprimis hereby represents and warrants to Lindstrom as follows:

 

2.3.1       All
Product to be supplied or sold pursuant to this Agreement shall comply with all applicable Federal, State and local regulations,
requirements and/or laws.

 

    	Page 3 of 12 

    	 

    

 

2.3.2       Imprimis
has full power and authority to execute this Agreement and to perform its obligations hereunder.

 

3.       License
Grant.

 

3.1       Licensed
IP Rights.

 

3.1.1       Lindstrom
hereby grants to Imprimis and its Affiliates an exclusive worldwide license under the Licensed IP Rights to conduct research and
to develop, formulate, make, have made, use, offer for sale, sell, sub-license, import and export the Product.

 

3.1.2       Imprimis
shall have the right to grant sublicenses under this Agreement consistent with the terms of this Agreement. Imprimis shall provide
Lindstrom with a copy of each executed sublicense agreement. Any sublicenses shall not diminish Imprimis’ obligations under
this Agreement, and Imprimis shall remain primarily liable for such obligations and for any breach of any provision of this Agreement
by its Affiliates or sublicensees.

 

3.1.3       During
the term of this Agreement, Lindstrom shall not grant to a Third Party any licenses that would become effective during the term
of this Agreement, related to products that may reasonably be considered competitive to the Product.

 

3.2       Availability
of the Licensed IP Rights. Lindstrom shall provide Imprimis with a copy of all information available to Lindstrom relating
to the Licensed IP Rights and/or Product.

 

3.3       Technical
Assistance. During the term of this Agreement, Lindstrom shall provide such technical assistance to Imprimis as Imprimis reasonably
requests regarding the Licensed IP Rights and/or Product. Imprimis shall pay to Lindstrom his documented reasonable pre-approved
out-of-pocket costs of providing such technical assistance.

 

4.       Royalties
and Milestone Payments.

 

4.1       Milestone
Payments.

 

4.1.1       Initial
Milestone Payment. An initial payment of Fifty Thousand Dollars ($50,000), payable at Imprimis’ election in cash or
shares of the Company’s restricted common stock1, par value $0.001 (“Common Stock”), within
fourteen (14) days of the Effective Date.

 

4.1.2       Periodic
Milestone Payments. Following the First Commercial Sale of the Product, Imprimis shall make two additional milestone payments
as follows:

  

 

1       In the event of any payments in shares of Common Stock, the number of shares of
Common Stock shall be calculated based upon the average closing price of the Company’s Common Stock for the five (5) days
prior to any issuance.

 

    	Page 4 of 12 

    	 

    

 

(a)       a
payment of Fifty Thousand Dollars ($50,000) payable at Imprimis’ election in cash or Common Stock within forty-five (45)
days following Fifty Thousand Dollars ($50,000) in Net Sales; and

 

(b)       an
additional payment of Fifty Thousand Dollars ($50,000) payable at the Company’s election in cash or Common Stock within
forty-five (45) days following One Hundred Thousand Dollars ($100,000) in Net Sales.

 

4.2       Royalties.

 

4.2.1       During
the applicable Royalty Period, subject to the terms and conditions of this Agreement, Imprimis shall pay to Lindstrom royalty
payments equal to six percent (6%) of Net Sales for Product.

 

4.2.2       During
the applicable Royalty Period, subject to the terms and conditions of this Agreement, Imprimis shall pay to Lindstrom royalty
payments equal to three percent (3%) of Net Sales for Combination Products.

 

4.2.3       The
parties have mutually agreed that this Agreement and the royalty structure set forth above reflects an arms’ length, fair
and reasonable allocation of the financial benefit accruing to each party from the development and commercialization of the Licensed
IP Rights throughout the entire Royalty Period for a Product.

 

4.3       Royalty
Reports. Within forty five (45) days after the end of each calendar quarter during the applicable Royalty Period, Imprimis
shall deliver to Lindstrom a report setting forth for such calendar quarter (a) the calculation of the applicable royalties due
under this Agreement for the sale of each Product; and (b) the volume of all Product(s) provided to Third Parties. Imprimis shall
remit the total payments due for the sale of Product during such calendar quarter at the time such report is made. No such reports
or payments will be due for any Product before the First Commercial Sale of such Product.

 

4.4       Audits.

 

4.4.1       Upon
the written request of Lindstrom and not more than once in each calendar year, Imprimis shall permit an independent certified
public accounting firm of nationally recognized standing selected by Lindstrom and reasonably acceptable to Imprimis, at Lindstrom’s
expense, to have access during normal business hours to such of the financial records of Imprimis as may be reasonably necessary
to verify the accuracy of the payment reports hereunder for the four (4) calendar quarters immediately prior to the date of such
request.

 

4.4.2       If
such accounting firm concludes that additional amounts were owed during the audited period, Imprimis shall pay such additional
amounts within thirty (30) days after the date Lindstrom delivers to Imprimis such accounting firm’s written report so concluding.
The fees charged by such accounting firm shall be paid by Lindstrom; provided, however, if the audit discloses that the
royalties payable by Imprimis for such period are more than one hundred ten percent (110%) of the royalties actually paid for
such period, then Imprimis shall pay the reasonable fees and expenses charged by such accounting firm

 

    	Page 5 of 12 

    	 

    

 

4.4.3       Lindstrom
shall cause its accounting firm to retain all financial information subject to review under this Section in strict confidence;
provided, however, that Imprimis shall have the right to require that such accounting firm, prior to conducting such audit,
enter into an appropriate non-disclosure agreement with Imprimis regarding such financial information. The accounting firm shall
disclose to Lindstrom only whether the reports are correct or not and the amount of any discrepancy. No other information shall
be shared. Lindstrom shall treat all such financial information as Imprimis’ Confidential Information (defined below).

 

4.5       Payment
Provisions.

 

4.5.1       Payment
Terms. The royalties shown to have accrued by each report provided for under this Section 4 shall be due on the date such
report is due. Payment of royalties in whole or in part may be made in advance of such due date.

 

4.5.2       Withholding
Taxes. Imprimis shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other taxes, levies
or charges with respect to such amounts, other than United States taxes, payable by Imprimis, its Affiliates or its or their respective
sublicensees, or any taxes required to be withheld by Imprimis, its Affiliates or its or their respective sublicensees, to the
extent Imprimis, its Affiliates or its or their respective sublicensees pay to the appropriate governmental authority on behalf
of Lindstrom such taxes, levies or charges. Imprimis shall use reasonable efforts to minimize any such taxes, levies or charges
required to be withheld on behalf of Lindstrom by Imprimis, its Affiliates or its or their respective sublicensees. Imprimis promptly
shall deliver to Lindstrom proof of payment of all such taxes, levies and other charges, together with copies of all communications
from or with such governmental authority with respect thereto.

 

5.       Indemnification.

 

5.1       Indemnification.
Each party (the “Indemnifying Party”) shall defend, indemnify and hold the other party (the “Indemnified
Party”) harmless from all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and
costs) incurred as a result of any Third Party claim, demand, action or proceeding to the extent arising out of any breach by
the Indemnifying Party of any representation, warranty or covenant set forth in this Agreement, or the gross negligence or willful
misconduct of the Indemnifying Party in the performance of its obligations under this Agreement.

 

    	Page 6 of 12 

    	 

    

 

5.2       Procedure.
The Indemnified Party promptly shall notify the Indemnifying Party of any liability or action in respect of which the Indemnified
Party intends to claim such indemnification, and the Indemnifying Party shall have the right to assume the defense thereof with
counsel selected by the Indemnifying Party. The indemnity agreement in this Section shall not apply to amounts paid in settlement
of any loss, claim, damage, liability or action if such settlement is effected without the consent of the Indemnifying Party,
which consent shall not be unreasonably withheld, delayed or conditioned. The failure to deliver notice to the Indemnifying Party
within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall
relieve the Indemnifying Party of any liability to the Indemnified Party under this Section, but the omission so to deliver notice
to the Indemnifying Party will not relieve it of any liability that it may have to the Indemnified Party otherwise than under
this Section. The Indemnified Party under this Section, its employees and agents, shall cooperate fully with the Indemnifying
Party and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification.

 

6.       Patents.

 

6.1       Patent
Prosecution and Maintenance. Lindstrom shall have the right at its sole expense to control the preparation, filing, prosecution
and maintenance of all patents and patent applications within the Licensed IP Rights. If Lindstrom elects not to file any such
patent application in any country, or decides to abandon any such pending application or issued patent in any country, Lindstrom
shall provide written notice to Imprimis, and Imprimis shall have the right at its sole expense to assume control of the preparation,
filing, prosecution and maintenance of such patent application or patent at its own expense.

 

6.2       
Enforcement of Patent Rights. Imprimis shall have the right at its sole expense and in its sole discretion to control the
enforcement and defense of the patents within the Licensed IP Rights against infringers of the Product, and to retain all amounts
recovered upon the final judgment or settlement thereof. Lindstrom shall, at the request of Imprimis, reasonably cooperate and
testify when requested and make available relevant documents, records, information, samples and other items in connection with
any action to enforce the patents within the Licensed IP Rights against infringers of the Product.

 

7.       Term
and Termination.

 

7.1       Term.
This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to this Section, shall continue in
effect until the expiration of Imprimis’ obligation to pay royalties to Lindstrom under this Agreement. The license grant
under this Agreement shall be effective at all times prior to termination or expiration of this Agreement

 

    	Page 7 of 12 

    	 

    

 

7.2       Termination.

 

7.2.1       Termination
by Imprimis. Except as otherwise provided in Section 8.4, Imprimis may terminate this Agreement upon or after the breach of
any material provision of this Agreement by Lindstrom if Lindstrom has not cured such breach within ninety (90) days after receipt
of express written notice thereof by Imprimis; provided, however, if any default is not capable of being cured within such ninety
(90) day period and Lindstrom is diligently undertaking to cure such default as soon as commercially feasible thereafter under
the circumstances, Imprimis shall have no right to terminate this Agreement for cause. In addition to the rights set forth in
the previous sentence, Imprimis shall have the right to terminate this Agreement at its option in its sole discretion upon one
hundred eighty (180) days written notice to Lindstrom.

 

7.2.2       Termination
by Lindstrom. Except as otherwise provided in Section 8.4, Lindstrom may terminate this Agreement upon or after the breach
of any material provision of this Agreement by Imprimis if Imprimis has not cured such breach within ninety (90) days after receipt
of express written notice thereof by Lindstrom; provided, however, if any default is not capable of being cured within such ninety
(90) day period and Imprimis is diligently undertaking to cure such default as soon as commercially feasible thereafter under
the circumstances, Lindstrom shall have no right to terminate this Agreement.

 

7.2.3       Termination
caused by Regulatory Mandate. If any state or federal regulatory body, including the FDA, interprets an existing or promulgates
a new rule, law or regulation that prohibits or otherwise materially adversely affects the exercise of rights licensed to Imprimis
under this Agreement, the parties shall use commercially reasonable efforts to take actions and/or amend this Agreement to promptly
and adequately address and account for such rules, laws or regulations. If such actions do not adequately address and account
for such rules, laws or regulations and/or the parties do not mutually agree on terms and conditions of an amendment to this Agreement
that addresses and accounts for such rules, laws or regulations, then either party may terminate this Agreement upon written notice
to the other party.

 

7.3       Survival.
Sections 5 (solely with respect to outstanding payment obligations as set forth therein), 7 and 8 shall survive termination or
expiration of this Agreement.

 

8.       Miscellaneous.

 

8.1       Public
Announcements. Neither party nor its Affiliates shall make any public announcements concerning matters regarding this Agreement
or the negotiation thereof without the prior written consent of the other party unless such disclosure is required by law, in
which case the announcing party shall provide the other party with reasonable notice of such disclosure sufficient to make written
comments concerning such disclosure.

 

    	Page 8 of 12 

    	 

    

 

8.2       Assignment.
Neither party shall assign its rights or obligations under this Agreement without the prior written consent of the other party;
provided, however, that a party may, without such consent, assign this Agreement and its rights and obligations hereunder (a)
to any Affiliate, or (b) in connection with the transfer or sale of all or substantially all of its business to which this Agreement
relates, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall
assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section shall be void.

 

8.3       Confidentiality.
Each party hereby agrees, and agrees to cause its Affiliates, stockholders, members, and representatives, to keep (a) the terms
of this Agreement and (b) any non-public, confidential or proprietary information of the other party confidential (collectively,
the “Confidential Information”) and, without limiting its other obligations hereunder, will treat and safeguard such
Confidential Information with the same degree of care with which it treats its own confidential information (but in no less a
reasonable degree of care) and to limit access to such terms to such employees, consultants, representatives and professional
advisors of such party who reasonably require such access in connection with the activities contemplated by this Agreement or
otherwise to administer the terms of this Agreement. To the extent practicable, in the event that a party is required to disclose
the Confidential Information pursuant to any law, regulation, or judicial or administrative directive, such party will promptly
notify the other party in order to allow the other party a reasonable period of time to obtain protective or confidential treatment
of such terms before they are disclosed. Either party may disclose the terms of this Agreement (i) to the extent required, in
the reasonable opinion of such party’s legal counsel, to comply with applicable laws, including, without limitation, the
rules and regulations promulgated by the United States Securities and Exchange Commission; and (ii) in connection with a prospective
acquisition, merger, financing, or license for such party, to prospective acquirers or merger candidates or to existing or potential
investors or licensees, provided that prior to such disclosure each such candidate or investor will agree to be bound by
obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section. Each party acknowledges
that it will be impossible to measure in money the damage to the other party if such party fails to comply with the obligations
imposed by this Section, and that, in the event of any such failure, the non-disclosing party may not have an adequate remedy
at law or in damages. Accordingly, each party agrees that injunctive relief or other equitable remedy, in addition to remedies
at law or damages, is an appropriate remedy for any such failure and will not oppose the granting of such relief on the basis
that the disclosing party has an adequate remedy at law. Each party agrees that it will not seek, and agrees to waive any requirement
for, the securing or posting of a bond in connection with the non-disclosing party seeking or obtaining such equitable relief.

 

8.4       Force
Majeure. Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted under or breached
this Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as,
such failure or delay is caused by or results from causes beyond the reasonable control of the affected party including but not
limited to fire, floods, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots,
civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental
authority or the other party.

 

    	Page 9 of 12 

    	 

    

 

8.5       Severability.
Any provision of this Agreement which is illegal, invalid or unenforceable shall be ineffective to the extent of such illegality,
invalidity or unenforceability, without affecting in any way the remaining provisions hereof.

 

8.6       Governing
Law; Exclusive Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of
California, without regard to the conflicts of law principles thereof.

 

8.7       Entire
Agreement; Amendment. This Agreement and each additional agreement and document to be executed and delivered pursuant hereto
constitute all of the agreements of the parties with respect to, and supersede all prior agreements and understandings relating
to the subject matter of, this Agreement or the transactions contemplated by this Agreement. This Agreement may not be modified
or amended except by a written instrument specifically referring to this Agreement signed by the parties hereto.

 

8.8       Waiver.
No waiver by one party of the other party’s obligations, or of any breach or default hereunder by any other party, shall
be valid or effective, unless such waiver is set forth in writing and is signed by the party giving such waiver; and no such waiver
shall be deemed a waiver of any subsequent breach or default of the same or similar nature or any other breach or default by such
other party.

 

8.9       Notices.
Any consent, notice or report required or permitted to be given or made under this Agreement by a party to the other party shall
be in writing, delivered by any lawful means to such other party at its address indicated below, or to such other address as the
addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this Agreement) shall be
effective upon receipt by the addressee.

 

	 	If
    to Lindstrom:	If
    to Imprimis:
	 	 	 
	 	 	Imprimis
    Pharmaceuticals, Inc.
	 	 	Attention:
    Mark L. Baum
	 	 	12264
    El Camino Real, Suite 350
	 	 	San
    Diego, California 92130
	 	 	E-mail:
    mark@imprimispharma.com

 

8.10       Counterparts.
This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

***SIGNATURE
PAGE FOLLOWS***

 

    	Page 10 of 12 

    	 

    

 

SIGNATURE
PAGE

 

IN
WITNESS WHEREOF, each party has caused a duly authorized representative to execute this Agreement on the Effective Date.

 

	LINDSTROM	 	IMPRIMIS
	 	 	 
	Dr.
    Richard L. Lindstrom	 	Imprimis
    Pharmaceuticals, Inc.
	 	 	 	 
	 	/s/
    Richard L. Lindstrom 	 	 	/s/
    Mark L. Baum
	By:	Dr.
    Richard L. Lindstrom	 	By:	Mark
    L. Baum
	 	An
    individual	 	Its:	Chief
    Executive Officer
	 	 	 	 	 
	Date:
    3/24/2017	 	Date:
    4/1/2017

 

[Signature
Page to License Agreement]

 

    	 

    	 

    

 

EXHIBIT
A

 

Licensed
Patent Rights

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]